IP Library Granted Patent US 12,102,710
Granted Patent B2
US 12,102,710 · App. 17/353,956 · Granted Oct 1, 2024

Probiotic skin formulations

Inventors: Thomas M. Hitchcock (Dallas, TX); Sasima Phadungpojna (Bristol, TN); Matthew D. Stephens (Kingsport, TN); Mun Su Rhee (Johnson City, TN)
Assignee: CROWN LABORATORIES, INC.
A61K8/99A61K8/022A61K8/042A61K8/19A61K8/34A61K8/37A61K8/671A61K8/735A61K8/88A61K8/922A61K8/9789A61K9/06A61K9/19A61K31/07A61K35/741A61K47/14A61K47/34A61K47/44A61K47/46A61Q19/00A61K2800/524A61K2800/594
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,102,710
App. No.
17/353,956
Granted
Oct 1, 2024
Kind
B2
Abstract

Described herein are dermatological compositions, formulations containing wild type or genetically modified Cutibacterium bacteria and methods for use thereof of skin. The cosmetic and therapeutic formulations described herein can be used as cosmetic daily skin treatments or for treating skin inflammation or disorders including acne, psoriasis, rosacea, dermatitis, or eczema.

Claims (10)

1. A dermatological composition consisting of:

an anhydrous formulation of:

about 0.1% to about 5% by mass of a dry growth-arrested genetically modified strain of Cutibacterium acnes ( C. acnes ) that remains in a dormant state for at least six months and up to about 2 years;

about 55% to about 95% by mass of one or more anhydrous emollients comprising ethyl olivate or Olea europaea leaf extract; and

about 1% to about 15% by mass of one or more anhydrous gelling agents comprising Polyamide-3.

2. A dermatological composition consisting of:

an anhydrous formulation of:

about 0.1% to about 5% by mass of a dry wild-type or growth-arrested genetically modified strain of Cutibacterium acnes ( C. acnes ) that remains in a dormant state for at least six months and up to about 2 years;

about 55% to about 95% by mass of one or more anhydrous emollients comprising ethyl olivate or Olea europaea leaf extract; and

about 1% to about 15% by mass of one or more anhydrous gelling agents comprising Polyamide-3.

Assignments (5)
SECURITY INTEREST Recorded Feb 7, 2025
From: REVANCE THERAPEUTICS, INC.; BELLUS MEDICAL, LLC; CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 070153/0736 →
SECURITY INTEREST Recorded Apr 16, 2024
From: CROWN LABORATORIES, INC.; STRIVECTIN OPERATING COMPANY, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 067117/0065 →
SECURITY INTEREST Recorded Jun 29, 2023
From: CROWN LABORATORIES, INC.; BELLUS MEDICAL, LLC; STRIVECTIN OPERATING COMPANY, INC.; NIADYNE, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 064112/0936 →
SECURITY INTEREST Recorded Jun 21, 2023
From: CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP
Reel/Frame 064014/0661 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2021
From: HITCHCOCK, THOMAS M.; PHADUNGPOJNA, SASIMA; STEPHENS, MATTHEW D.; RHEE, MUN SU
To: CROWN LABORATORIES, INC.
Reel/Frame 056614/0538 →